Date:11/17/2010

ain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 as filed with the SEC on November 9, 2010, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations

Kim Baker/Gene CarozzaPAREXEL International

PAN CommunicationsTel: +781-434-4409

Tel: + 978-474-1900Email: Jennifer.Baird@PAREXEL.com

Email: PAREXEL@pancomm.com
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology news :

1. Team completes world-first ocean observatory
2. University of Hawaii completes 3-year investigation of military munitions sea disposal site
3. Kornberg Associates
4. Architects Completes UC Riverside Stem Cell Core Facility Project
5. KINAXO Completes Financing Round to Enhance Biomarker Development
6. Pacific Biometrics Completes $4 Million Debt Financing
7. InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
8. Lockheed Martin Team Completes Key Design Milestone on Federal Bureau of Investigations Next Generation Identification Program
9. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
10. DOE Joint Genome Institute completes soybean genome
11. Arsenic early in treatment improves survival for leukemia patients